Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha ®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha ®, treat according to the standard of care, and monitor until signs and symptoms resolve.Īdverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha ® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.įrom a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha ®-treated and placebo-treated patients, respectively. Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha ®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha ®. ††All claims were approved with an attestation only through CoverMyMeds.Ĭontraindications: Repatha ® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha ®. These statistics are subject to change and are based upon a multitude of factors that can influence turnaround time. **Data from Januthrough December 31, 2022, measuring time between when a complete ePA is submitted to the health plan and determination is received by the HCP. CoverMyMeds is a registered trademark of CoverMyMeds LLC. §Amgen ®, the marketer of Repatha ®, has entered into a fee-for-service arrangement with CoverMyMeds to provide a differentiated ePA experience after you have chosen to prescribe Repatha ®. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic. Medicare Part D drug coverage is divided into four phases, each with a different cost-sharing amount. †The patient out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in. *Subject to eligible criteria and program maximums. If you are having difficulty accessing this website, please call or email us at 1-85 or so that we can provide you with the services you require through alternative means.NRx, new prescription PCSK9, proprotein convertase subtilisin/kexin type 9 PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor. ![]() GoodRx works to make its website accessible to all, including those with disabilities. ![]() Truven Health does not assume any responsibility or risk for your use of the Truven Health products. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Additionally, TRUVEN HEALTH MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. Truven Health and GoodRx make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. These products are provided 'AS IS' and 'as available' for use, without warranties of any kind, either express or implied. The use of the Truven Health products is at your sole risk.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |